The association between EAF2 and hepatocellular carcinoma can be explained by the fact that EAF2 deficiency increases the risk of hepatic vascular lesions, which subsequently leads to hepatocyte loss, hepatic fibrosis, and eventually hepatocellular carcinoma via the pVHL pathway in mice (Pascal et al., 2011). Here, EAF2 is linked to hepatocellular carcinoma.